Dansk | English
Sitemap
youtube_off.png
linkedin_off.png
Facebook
News

News

Dato
18.04.2017
BONESUPPORT™ appoints Michael Diefenbeck as Chief Medical Officer

Lund, Sweden, 11th April, 2017 – BONESUPPORT AB, an emerging leader in innovative injectable bioceramic bone scaffolds to treat bone voids caused by trauma, infection, disease or related surgery, announces the appointment of Michael Diefenbeck MD PhD as Chief Medical Officer.

Dr Diefenbeck founded Scientific Consulting in Orthopaedic Surgery in 2014 and has worked for BONESUPPORT on a range of clinical projects related to CERAMENT™ as an independent clinical advisor. 

Dato
06.04.2017
ICONIC THERAPEUTICS APPOINTS JULIA P. GREGORY TO BOARD OF DIRECTORS
South San Francisco, April 6, 2017 – – Iconic Therapeutics, a clinical stage biopharmaceutical company dedicated to translating knowledge of Tissue Factor biology into new therapeutics for retinal disease and cancer, announced today the addition of Julia P. Gregory to the company’s Board of Directors.
Dato
04.04.2017
Sucampo Acquires Vtesse Inc.
Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, and Vtesse Inc. (Vtesse), a privately-held rare disease company, today  announced that Sucampo has acquired Vtesse for upfront consideration of $200 million. Sucampo funded the acquisition through the issuance of 2,782,678 shares of Sucampo Class A common stock and $170 million of cash on hand;  no  external  financing  was utilized.

Dato
16.03.2017
BONESUPPORT™ Founder Lars Lidgren Receives the 2017 OREF Clinical Research Kappa Delta Award
Lund, Sweden, 16 March, 2017 – BONESUPPORT AB, an emerging leader in innovative injectable bioceramic bone scaffolds to treat bone voids caused by trauma, infection, disease or related surgery, announces that its founder Lars Lidgren, is a member of a  group of Swedish and US Knee and Hip surgeons from Lund and Gothenburg, Sweden, Boston and Rochester U.S. that has received the 2017 OREF Clinical Research Kappa Delta Award. The award was made for the group’s outstanding research contribution leading to improved prosthetic survival and patient outcomes.
Dato
15.03.2017
Vtesse Completes Enrollment of Phase 2b/3 Pivotal Clinical Trial of VTS-270 in Niemann-Pick Type C1 Disease

Company anticipates sharing topline data and completing regulatory submissions in 2018

GAITHERSBURG, Md., March 15, 2017 /PRNewswire/ -- Vtesse, Inc. announced today that its registrational study of investigational drug VTS-270 in Niemann-Pick Type C1 disease (NPC) is fully enrolled. 

Dato
14.03.2017
BONESUPPORTTM EXTENDS U.S. DISTRIBUTION AGREEMENT FOR CERAMENTTM|BONE VOID FILLER
Lund, Sweden, 14 March, 2017 – BONESUPPORT AB, an emerging leader in innovative injectable bioceramic bone scaffolds to treat bone voids caused by trauma, infection, disease or related surgery, announces that it has extended the term of its U.S. distribution agreement with Zimmer Biomet.  Under the agreement, Zimmer Biomet will continue to have exclusive rights for BONESUPPORT’s proprietary CERAMENT BONE VOID FILLER product line for Orthopedics, Trauma and Foot and Ankle indications in the United States.
Dato
10.03.2017
Spero Therapeutics Secures $51.7 Million in Oversubscribed Series C Financing

$51.7 million financing broadens investor base and provides flexibility to advance clinical stage potentiator program and expand antibacterial pipeline

CAMBRIDGE, Mass, March 8, 2017 – Spero Therapeutics, LLC, a biopharmaceutical company founded to develop novel therapies to treat bacterial infections, announced today that it has completed a $51.7 million Series C preferred financing led by new investor GV (formerly Google Ventures). The round includes participation by additional new investors RA Capital Management and Rock Springs Capital as well as existing investors. 

Dato
21.02.2017
First patients entered into Phase II trial of VHsquared's lead Vorabody product V565 HARBOR study of novel anti-TNFα oral domain antibody taking place in North America & Europe

Cambridge, UK, February 20 2017 – VHsquared, the oral domain antibody company, is pleased to announce that the first patients have entered the international Phase II trial of its lead product, V565, in Crohn's disease. The aim of the HARBOR study1 is to show the efficacy of the anti-TNFα oral domain antibody as measured by changes in clinical symptoms, markers of inflammation and endoscopic appearance. It is randomised, doubleblind and placebo-controlled, involving over 100 patients with moderately to severely active Crohn’s disease. VHsquared is developing a portfolio of complementary oral domain antibodies (Vorabodies) which engage validated biological targets with the potential to transform the treatment of inflammatory bowel disease (IBD).

Dato
13.02.2017
ACACIA PHARMA ANNOUNCES POSITIVE RESULTS FROM ITS FOURTH AND FINAL PIVOTAL TRIAL OF BAREMSIS™ FOR THE RESCUE TREATMENT OF PONV

Extensive Phase 3 programme demonstrates clinical potential of BAREMSIS in rescue treatment and prophylaxis of PONV – NDA to be submitted to the US FDA 1H 2017

Cambridge, UK – 13th February 2017: Acacia Pharma Group Ltd (“Acacia Pharma”), the supportive care company developing products for US and international markets, announces positive results from its fourth and final pivotal Phase 3 study investigating BAREMSIS™ (amisulpride injection, formerly APD421) for the rescue treatment of patients who develop post-operative nausea & vomiting (PONV), despite having received prior antiemetic prophylaxis.  

Dato
10.02.2017
ICONIC THERAPEUTICS TO PRESENT PHASE 2a EMERGE TRIAL RESULTS AT MIAMI MEETING
South San Francisco, February 9 – – Iconic Therapeutics, a clinical stage biopharmaceutical company dedicated to translating knowledge of Tissue Factor biology into new therapeutics for retinal disease and cancer, announced today that the results of its recently completed EMERGE trial, a Phase 2a randomized, double-masked, multi-dose study of the drug candidate ICON-1 in wet Age-Related Macular Degeneration (AMD), will be presented for the first time at the Angiogenesis, Exudation, and Degeneration meeting in Miami, FL on Saturday February 11. The trial design included assessment of outcomes specifically designed to measure lesion growth and leakage, both hallmarks of disease progression in AMD. The EMERGE trial was a six-month, active-controlled, multi-center study of 88 patients with newly diagnosed disease. Iconic previously completed an 18-subject Phase 1 clinical trial in neovascular AMD, which demonstrated safety and preliminary evidence of potential biologic activity
1 2 3 4 5 6 7 8 9 10 Næste 10 Næste